Bomedemstat Medicine 07 December 2022 Extended indication Essential thrombocythaemia and myelofibrosis. Therapeutic value No estimate possible yet Total cost Registration phase Clinical trials Product Active substance Bomedemstat Domain Hematology Reason of inclusion New medicine (specialité) Main indication Myeloproliferative disorders Extended indication Essential thrombocythaemia and myelofibrosis. Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer Imago Portfolio holder Mechanism of action Unknown Route of administration Oral Therapeutical formulation Capsule Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Lysine specific demethylase 1 inhibitor. Registration Registration route Centralised (EMA) Type of trajectory Unknown Particularity Unknown ATMP No Submission date 2024 Expected Registration 2025 Orphan drug Yes Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration 1 times a day Dosage per administration References NCT05223920 Additional remarks Expected patient volume per year Patient volume < 166 Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References NKR 2018 (1); Additional remarks In totaal waren er 166 diagnoses in 2018 (1). Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks